Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9192984 | 0.81 | AKR1B1 (0.51) | KMT2AALDH1A1MAPTAKR1B1KDM4E | |
| SCHEMBL16984016 | 0.76 | ALDH1A1 (0.35) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL11908469 | 0.74 | ALDH1A1 (0.46) | EGLN3MEN1KMT2ALMNAFABP3 | |
| SCHEMBL11334483 | 0.73 | NPC1 (0.42) | LMNAALDH1A1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL6348803 | 0.71 | TYR (0.55) | EGLN3MEN1KMT2ALMNAFABP3 | |
| SCHEMBL11337869 | 0.71 | NPC1 (0.49) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL23541176 | 0.70 | EGLN3 (0.43) | EGLN3MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL22342727 | 0.70 | NPC1 (0.50) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL22342731 | 0.70 | NPC1 (0.50) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL22342726 | 0.70 | NPC1 (0.50) | MEN1KMT2ALMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119751188-A | Screening preparation method and application of anti-inflammatory and antioxidant activity of ramulus et folium Broussonetiae extract | 云南农业大学 | 2025-04-04 | — | — | CN | claimed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11376334-B2 | Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-07-05 | — | — | US | disclosed |
| US-11376334-B2 | Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-07-05 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-20200405876-A1 | Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2020-12-31 | — | — | US | disclosed |
| US-20200405876-A1 | Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2020-12-31 | — | — | US | disclosed |
| US-10758628-B2 | Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190192680-A1 | Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate | REDWOOD BIOSCIENCE, INC. | 2019-06-27 | — | — | US | disclosed |
| US-10195283-B2 | Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2019-02-05 | — | — | US | disclosed |
| US-10195283-B2 | Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2019-02-05 | — | — | US | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20170266302-A1 | Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate | R.P. SCHERER TECHNOLOGIES, LLC | 2017-09-21 | — | — | US | disclosed |
| US-20170266302-A1 | Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate | R.P. SCHERER TECHNOLOGIES, LLC | 2017-09-21 | — | — | US | disclosed |
| US-20170266302-A1 | Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate | R.P. SCHERER TECHNOLOGIES, LLC | 2017-09-21 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10195283-B2 | Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate | HNMT, TIAL1, HACL2 | EGLN3 1515/4885MEN1 491/4885KMT2A 515/4885 |
| US-20190192680-A1 | Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate | HNMT, TIAL1, HACL2 | EGLN3 1515/4885MEN1 491/4885KMT2A 515/4885 |
| US-20170266302-A1 | Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate | HNMT, TIAL1, HACL2 | EGLN3 1515/4885MEN1 491/4885KMT2A 515/4885 |
| US-11376334-B2 | Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate | HNMT, TIAL1, HACL2 | EGLN3 1515/4885MEN1 491/4885KMT2A 515/4885 |
| US-10758628-B2 | Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate | HNMT, TIAL1, HACL2 | EGLN3 1515/4885MEN1 491/4885KMT2A 515/4885 |
| US-20200405876-A1 | Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate | HNMT, TIAL1, HACL2 | EGLN3 1515/4885MEN1 491/4885KMT2A 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.